PrismaLung+
Support management of acute respiratory dysfunction with ECCO2R
Extracorporeal carbon dioxide removal (ECCO2R) therapy removes CO2 from a patient’s blood to effectively manage acute hypercapnia and respiratory acidosis to facilitate the use of lung-protective ventilation (LPV) or ultra lung-protective ventilation (ULPV) in patients with ARDS2-5 as well as enable the use of NIV strategies in patients with aeCOPD which may reduce the need for intubation. For patients with multiple organ dysfunction, the therapy can also be integrated with other therapies delivered on a single platform.
Deliver ECCO2R as standalone or in combination with other therapies6
ECCO₂R
Deliver stand-alone ECCO2R to support management of acute respiratory dysfunction
ECCO₂R and CRRT combined
Combine therapies to support management of acute respiratory dysfunction and acute kidney injury
ECCO₂R, CRRT, and blood purification for sepsis management simultaneously
Add blood purification for sepsis management to simultaneously support management of acute respiratory dysfunction and AKI in patients who may benefit from removal of endotoxins and inflammatory mediators – all with one vascular access point
Example of ECCO2R and CRRT set-up
Optimize CO₂ removal with smaller membrane for risk management
The PrismaLung+ blood-gas exchanger delivers CO2 removal equivalent to that of a device with a larger surface area, while addressing risks that may be associated with extracorporeal therapies:
- Smaller membrane size to help reduce clotting risk
- Lower extracorporeal blood volume
An in vitro study shows that at the same blood flow rates and the same initial PaCO2 levels, the PrismaLung+ blood-gas exchanger (0.8m2) provides similar CO2 removal rate performance when compared to a much larger membrane.7
The PrismaLung+ blood-gas exchanger removes CO2 at blood flow rates ≤ 450 mL/min as effectively as a device with a larger surface area.7
Vascular Access Performance
By operating at blood flow rates similar to CRRT and using the same vascular access, the PrismaLung+ blood-gas exchanger limits the invasiveness of ECCO2R therapy compared to mid-flow ECCO2R and vv-ECMO. The PrismaLung+ blood-gas exchanger works with any brand catheter, and can be used with Baxter’s GamCath GDHK-1320 catheter, which has demonstrated one of the best access and return pressure performances at various blood flow rates when compared to other brands and designs including bigger catheter sizes (13, 14 and 15FR).8
The PrismaLung+ blood-gas exchanger is an ECCO2R therapy device designed to be used as part of the PrisMax 2 organ support system1
Maintain patient blood temperature6
When integrated with the PrisMax 2 system, the PrismaLung+ blood-gas exchanger uses the TherMax blood warmer to provide an advanced source of support for efficient and easy patient blood warming. Automatic blood heating adjustment helps meet the prescribed return blood temperature independently from blood flow rates and therapy interruptions.
Optimized ECCO₂R delivery with smart efficiencies
Integrate ECCO2R therapy into your existing CRRT setup with the PrismaLung+ blood-gas exchanger on the PrisMax 2 system and reduce the need for additional capital expenditure and monitor maintenance while minimizing staff training requirements.
Reduce the need for additional investments and monitor maintenance
Run all therapies (CRRT, TPE, ECCO2R, blood purification for sepsis management) and modalities (SCUF, CVVH, CVVHD, CVVHDF) using just one monitor with the PrisMax 2 system.
Optimize staff workload and training
Streamline ECCO2R treatment setup with step-by-step software guidance through the intuitive PrisMax 2 interface. Providing a setup and implementation routine similar to CRRT enables easy integration of the new therapy with limited training effort.
The PrismaLung+ blood-gas exchanger is easily added to the CRRT set and the whole set is automatically one-step primed which means interactions during setup is similar to CRRT.
Enhance overall treatment accuracy
Help improve patient fluid balance accuracy with Baxter’s patented software algorithm estimating normal phenomenon of water evaporation during ECCO2R treatment.6
Related Products
ACRONYMS
ARDS = Acute Respiratory Distress Syndrome
aeCOPD = Acute Exacerbation of Chronic Obstructive Pulmonary Disease
LPV = Lung Protective Ventilation
ULPV = Ultraprotective Lung Protective Ventilation
VILI = Ventilation Induced Lung Injury
NIV = non-Invasive Ventilation
IMPORTANT SAFETY INFORMATION
The PrisMax control unit is intended for:
- Continuous Renal Replacement Therapy (CRRT) for patients with acute renal failure and/or fluid overload.
- Therapeutic Plasma Exchange (TPE) therapy for patients with diseases where removal of plasma components is indicated.
- Hemoperfusion (HP) for patients with conditions where immediate removal of substances by adsorption is indicated.
- Extracorporeal CO2 Removal (ECCO2R) for patients with conditions where extracorporeal elimination of carbon dioxide is indicated.
The PrismaLung+ device is indicated to provide extracorporeal CO2 removal (ECCO2R) as a stand-alone therapy or in combination with Continuous Renal Replacement Therapy (CRRT). It is intended for patients with increased levels of CO2 in their blood and with a body weight greater than or equal to 30 kg (66 lb).
The TherMax blood warmer is intended for use in combination with the PrisMax control unit using Prismaflex blood tubing sets for the warming of blood during extracorporeal blood circulation.
The GamCath Dolphin Protect Catheters are intended for short-term use. They are used to obtain vascular access to perform extracorporeal blood purification. They can be used in the subclavian, jugular or femoral veins. These catheters are not intended to be used as a treatment for existing infections.
For safe and proper use of the products mentioned herein, please refer to the Operator’s Manual or Instructions for Use.
